These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38721949)

  • 21. Impact of COVID-19 pandemic on the course of refractory chronic spontaneous urticaria under omalizumab treatment.
    Olgaç M; Yeğit OO; Beyaz Ş; Öztop N; Tüzer C; Eyice D; Karadağ P; Coşkun R; Demir S; Çolakoğlu B; Büyüköztürk S; Gelincik A
    An Bras Dermatol; 2023; 98(2):189-197. PubMed ID: 36609081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
    Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
    Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does omalizumab use in chronic spontaneous urticaria results in improvement in sexual functions?
    Durmaz K; Ataseven A; Temiz SA; Isik B; Dursun R
    J Cosmet Dermatol; 2022 Oct; 21(10):4877-4881. PubMed ID: 35184358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
    Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
    J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients.
    Kulthanan K; Tuchinda P; Likitwattananurak C; Weerasubpong P; Chularojanamontri L
    J Dermatol; 2018 Jan; 45(1):17-23. PubMed ID: 29044681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
    Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
    [No Abstract]   [Full Text] [Related]  

  • 32. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 33. Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.
    Sirufo MM; Bassino EM; De Pietro F; Ginaldi L; De Martinis M
    Int J Immunopathol Pharmacol; 2021; 35():20587384211065870. PubMed ID: 35170369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of omalizumab treatment on peripheral nerves in patients with chronic spontaneous urticaria.
    Altunisik E; Inan Dogan E
    Cutan Ocul Toxicol; 2021 Jun; 40(2):130-134. PubMed ID: 33902373
    [No Abstract]   [Full Text] [Related]  

  • 35. Lower efficacy of omalizumab in older adults with chronic spontaneous urticaria.
    Kitao R; Oda Y; Washio K; Tai Y; Ono R; Nishigori C; Fukunaga A
    J Dermatol; 2022 Jul; 49(7):729-731. PubMed ID: 35352836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
    Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria.
    Keskinkaya Z; Kaya Ö; Işık Mermutlu S; Öğretmen Z
    Int Arch Allergy Immunol; 2024; 185(8):786-793. PubMed ID: 38626739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
    Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
    Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
    Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
    Salman A; Comert E
    J Cutan Med Surg; 2019; 23(5):496-500. PubMed ID: 31030540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.